Bisphosphonates (BP) are potent inhibitors of bone resorption that inhibit the activity of osteoclasts. All approved bisphosphonates have been shown to reduce vertebral fracture risk and increase BMD, whereas some have demonstrated reductions in non-vertebral and hip fracture risk as well.

They are available in oral and intravenous formulations, with weekly, monthly and annual dosing schedules, depending on the specific agent. Bisphosphponates bind to bone mineral, and consequently have a long skeletal retention. Orally administered BPs have a poor intestinal absorption and can induced mild intestinal disturbances.


Alendronate decreases bone resorption and formation markers, increases BMD and reduces the incidence of fractures by 30 to 50 % in women with established osteoporosis (1). The anti-fracture efficacy has been shown both in women with prevalent vertebral fractures and in women with low BMD (T-score<-2) but without vertebral fractures [1,2].

Meta-analysis carried out on the basis of several studies in postmenopausal and elderly osteoporotic women showed that alendronate decreases the risk of hip fracture by about 45 % [3]. Bridging studies showed that once-weekly alendronate at the dose of 70 mg is therapeutically equivalent to the reference daily regimen (similar increase in BMD, similar decrease in bone turnover marker (BTM) levels) [4]. In early postmenopausal women, a smaller dose of alendronate (5 mg) prevents bone loss [5].

In osteoporotic men, alendronate increases BMD at the lumbar spine and hip and decreases the incidence of vertebral fractures [6].

Alendronate also prevents bone loss in men receiving androgen deprivation therapy for prostate cancer [7] and is effective in the treatment of glucocorticoid-induced osteoporosis [8]. Rare cases of esophagitis have been reported. 


Risedronate decreases the incidence of new vertebral and peripheral fractures by the same extent as alendronate in women with low BMD and in women with prevalent vertebral fractures [9,10]. In osteoporotic women 70 to 79 years of age, risedronate decreased the incidence of hip fracture by 40 % [11]. Bridging studies showed that alternative doses of risedronate (35 mg once a week, 75 mg on two consecutive days a month, 150 mg once a month) decrease the BTM levels and increase BMD to a similar extent as the daily regimen [12-14]. Also in men with low BMD, risedronate decreased bone turnover and increased BMD [15]. The efficacy of risedronate has also been shown in the prevention and treatment of glucocorticoid -induced osteoporosis [16].

In a post-hoc analysis carried out in data combined from four phase III studies, risedronate reduced the incidence of fractures within 6 months of treatment [17]. Some [18], but not all [19], observational studies suggest that the anti-fracture efficacy of risedronate appears earlier than that of alendronate. However, these analyses are based on the retrospective analyses of the databases of the healthcare providers and no randomized head-to-head studies permitting direct comparisons were performed.


Ibandronate is commercially available as an oral daily regimen (2.5 mg/day), oral monthly regimen (150 mg once monthly) and intravenous form (3 mg intravenously every 3 months). In postmenopausal osteoporotic women, oral ibandronate administered daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months) induced a rapid, pronounced and persistent decrease in bone turnover, increased BMD and reduced the incidence of vertebral fractures by at least 50 % [20,21]. Oral ibandronate administered at the dose of 150 mg once monthly induced a greater decrease in the BTM levels and a significantly greater increase in BMD than the daily ibandronate [22].

Once-monthly ibandronate (150 mg) also reduced the risk of vertebral fractures to a similar extent as weekly alendronate and risedronate [23]. In postmenopausal osteoporotic women, intravenous ibandronate (2 mg every 2 months or 3 mg every 3 months) induced a similar decrease in the BTM levels, a greater increase in BMD and a similar reduction in the incidence of clinical fractures in comparison with daily ibandronate [24].

Meta-analyses of the results of all the existing studies showed that the annual cumulative exposure (ACE) to ibandronate higher than 10.8 mg was associated with a decrease in the incidence of the non-vertebral fractures by about 30 to 40 % [25,26]. (Please note: calculation of ACE takes account of the intestinal absorption of a drug and corresponds to its quantity which is available to bone tissue.) In male cardiac transplant patients, ibandronate (2 mg i.v. every 3 months) decreased the BTM levels, prevented bone loss and reduced the incidence of vertebral fractures [27].

Zoledronic acid

Zoledronic acid administered intravenously to postmenopausal women with osteoporosis at a dose of 5 mg once-yearly induced a sustained decrease in bone turnover, a progressive increase in BMD and a significant decrease in the incidence of vertebral fractures by 70 % and in the incidence of non-vertebral fractures by 25 % (including a significant 40 % decrease in the incidence of hip fractures) [28].

In older men and women with recent low trauma hip fracture (two weeks or later but less than 90 days after surgical repair) zoledronic acid increased BMD at the hip, decreased the incidence of clinical fractures (including a significant decrease in the incidence of hip fracture) and reduced the mortality rate by about 30 % [29,30]. In men and women treated with oral glucocorticoids, zoledronic acid induced a greater decrease in the rate of bone turnover and a greater increase in BMD compared with risedronate [31]. In men receiving androgen deprivation therapy for prostate cancer, zoledronate slowed bone turnover and prevented bone loss [32].

Possible side effects and limitations of bisphosphonates

Recently, several issues related to long-term use of BPs have been raised. An important and associated question is how long patients should be treated with BPs? BPs are potent suppressors of bone resorption and may lead to a phenomenon called “severely suppressed bone turnover” [33], particularly in patients on glucocorticoid therapy and/or concommitent anti-resorptive therapy, such as HRT. Such extreme inhibition of bone remodeling may theoretically lead to an accumulation of microdamage which might compromise bone strength and increase the risk of low trauma fracture or delay fracture healing [33-35]. However, iliac crest biopsies from women on long-term bisphosphonate do not show increased microdamage [36], and clinical trials of bisphophonates did not show evidence of altered healing.

To avoid potential side effects, many clinicians consider it apropriate to re-evalute the patients fracture risk after 5 years of treatment, and then consider whether to stop or continue the treatment. There is limited evidence to support this key clinical decision. In the FLEX trial, withdrawal of alendronate after 5 years of treatment was followed by a mild decrease in BMD (at some, but not all sites) and a mild increase in BTM levels [37,38].

In another study, fracture incidence after BP discontinuation increased in women who took BPs for 2 years with a suboptimal adherence [39]. By contrast, after discontinuation of the long term treatment with alendronate in the FLEX study, fracture incidence remained reduced for 5 years, except for a slightly higher risk of clinical vertebral fractures in comparison with women who took alendronate continuously [37]. However, there was no placebo group in this study, so it is difficult to draw firm conclusions. Thus, there are no evidence-based guidelines how long osteoporotic patients should take BPs. However, on the basis of the available clinical and pre-clinical data, it can be inferred that, in the vast majority of patients, stopping therapy is more likely to do harm than continuing therapy [40].

Osteonecrosis of the jaw (ONJ) is observed in patients with various malignancies who are treated for a long period of time with high doses of BPs [41,42]. By contrast, cases of ONJ in the osteoporotic patients are extremely rare – no case was found in more than 3000 patients participating in the clinical trials with zoledronate and alendronate [28,29,37] and no causal link between ONJ and BP therapy in these patients has been convincingly demonstrated. Precipitating factors for ONJ, which occurs in people who have never received BP therapy, include dental surgery, ill-fitted dental prosthesis and aggravating factors (heavy smoking, infection) [43-45]. Clinical data do not support the use of BTM (e.g. serum CTX-I concentration) as predictors of the risk of ONJ in the bisphosphonate-treated patients [46].

Recent case reports have suggested a higher occurrence of atypical femoral shaft fractures (subtrochanteric or proximal diaphyseal fracture) in a select group of women and men treated long-term with alendronate, particularly in those receiving glucocorticoids and/or another anti-resorptive medication such as estrogen (47-52). It is not clear if these fractures are related to long-term alendronate treatment or rather are a form of fragility fracture in osteoporotic patients. These fractures are generally thought to be low trauma fractures occurring in patients who have taken alendronate for several years (usually > 5).

Prior to their fracture, these patients often, but not always, had experienced persistent pain in the thigh that was, aggravated during standing and resistant to analgesics. Individuals with these types of fractures appear to have modest cortical thickening of the femur diaphysis, and bone scintigraphy shows increased uptake of the radioisotope in the subtrochanteric area at the site of the cortical thickening which can be bilateral, and which is consistent with a stress fracture.

From the practical point of view, two points are important. Firstly, a pain in the thigh not related to trauma and aggravating during standing needs further investigation when it is reported by a patient treated with alendronate. Secondly, it is advisable to discontinue alendronate in patients with normal BMD values on long-term glucocorticoid treatment. Obviously, these suggestions are always true, but particularly relevant in the context of the femoral shaft fractures. Additional studies are needed to determine the mechansims underlying these fractures and the characteristics of the few patients that may be at increased risk for this injury.

Treatment with BPs was associated with higher risk of atrial fibrillation in some [28,53,54], but not all [55,56], studies. The association between use of BPs and risk of atrial arrhythmia and its clinical significance remains to be elucidated. Women treated for osteoporosis may have a higher cardiovascular risk before the beginning of the BP treatment than non-osteoporotic women. During treatment with zoledronate, electrolyte imbalance does not seem to precipitate the atrial arrhythmia, because episodes of atrial fibrillation did not cluster in time after infusions, when serum electrolytes are most affected [28].


1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
2. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 85:4118-4124
3. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE 2005 Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 16:468-474
4. Rizzoli R, Greenspan SL, Bone G 3rd, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC 2nd, Kaur A, Peverly CA, Orloff JJ 2002 Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17:1988-1996
5. McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P 1998 Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 128:253-261
6. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610
7. Greenspan SL, Nelson JB, Trump DL, Resnick NM 2007 Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146:416-424
8. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292-299
9. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
10. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91
11. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340.
12. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R 2002 The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103-111
13. Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R, Zanchetta J, Olszynski WP, Recker RR, McClung MR 2008 Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 19:1039-1045
14. Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S 2008 Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36-42
15. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD 2009 Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719-725
16. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA 1999 Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309-2318
17. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S 2004 Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129-135
18. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R 2007 Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25-34
19. Curtis JR, Westfall AO, Cheng H, Saag KG, Delzell E 2009 RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int 20:973-978
20. Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C 2004 Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792-798
21Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
22. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD 2006 Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654-661
23. Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL 2009 Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 44:758-765
24. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM 2006 Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838-1846
25. Harris ST, Blumentals WA, Miller PD 2008 Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237-245
26. Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, Miller PD, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adachi JD 2009 Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 20:291-297
27. Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, Obermayer-Pietsch BM, Pilz S, Dimai HP, Prenner G, Tscheliessnigg KH, Hauge E, Portugaller RH, Dobnig H 2009 Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 24:1335-1344
28. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
29. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S 2007 Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809
30. Eriksen EF, Lyles KW, Colón-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P 2009 Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24:1308-1313
31. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253-1263
32. Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S 2009 Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer 115:3468-3474
33. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301
34. Visekruna M, Wilson D, McKiernan FE 2008 Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948-2952
35. Rozental TD, Vazquez MA, Chacko AT, Ayogu N, Bouxsein ML 2009 Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg Am 34:595-602
36. Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, Delmas PD 2007 Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22:1502-1509.
37. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
38. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199
39. Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG 2008 Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19:1613-1620.
40. Seeman E 2009 To stop or not to stop, that is the question. Osteoporos Int 20:187-195
41. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN 2008 Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826-836
42. Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, Delaroudis S 2007 Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol 28:158-163
43. Silverman SL, Landesberg R 2009 Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 122(2 Suppl):S33-45.
44. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY 2008 Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42:841-847.
45. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S 2007 Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18:1363-1370
46. Baim S, Miller PD 2009 Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 24:561-574
47. Abrahamsen B, Eiken P, Eastell R 2009 Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095-1102
48. Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE 2009 Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 24:1736-1740
49. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS 2007 Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349-353
50. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS 2008 An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224-231.
51. Lenart BA, Lorich DG, Lane JM 2008 Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304-1306
52. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM 2009 Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353-1562
53. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM 2008 Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168:826-831
54. Abrahamsen B, Eiken P, Brixen K 2009 Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 265:581-592
55. Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG, Weiss JP, Lappé DL, Osborn JS, Day JD 2009 Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824-828
56. Sørensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA 2008 Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336:813-816